Feds Greenlight Bulk LSD and THC Maker: Trippy Times Ahead?
Published Date: 3/10/2026
Notice
Summary
Sigma Aldrich Research Biochemicals Inc. wants to become an official bulk maker of some powerful controlled substances, including LSD and THC. People and companies involved with these drugs can share their thoughts or ask for a hearing by May 11, 2026. This move could impact how these substances are produced and regulated, but no direct costs are mentioned yet.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 0 costs, 1 mixed.
Sigma Aldrich Seeks Bulk-Drug Registration
On December 18, 2025, Sigma Aldrich Research Biochemicals Inc. applied to be registered as a bulk manufacturer for many Schedule I and II controlled substances, including lysergic acid diethylamide (LSD) and tetrahydrocannabinols (THC). The company says it plans to manufacture the listed substances only as reference standards, and interested parties may submit comments or request a hearing on or before May 11, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-13821 — Schedules of Controlled Substances: Placement of Tianeptine in Schedule I
The DEA wants to put tianeptine, a drug with potential risks, into Schedule I, meaning it’ll be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or uses tianeptine, bringing strict rules and penalties. You’ve got until August 7, 2026, to share your thoughts before the new rules could kick in.
2026-13705 — Importer of Controlled Substances Application: Benuvia Operations, LLC.
Benuvia Operations, LLC wants to become an official importer of certain controlled substances like marijuana extract and psilocybin. People and companies involved with these drugs can share their thoughts or ask for a hearing by August 6, 2026. This move could shake up who gets to bring these substances into the U.S., so keep an eye on the deadline if you’re interested!
2026-13581 — Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I
Starting July 6, 2026, the DEA plans to temporarily put three substances related to 7-hydroxymitragynine—Mitragynine Pseudoindoxyl, MGM-15, and MGM-16—into Schedule I, the strictest drug category. This means anyone making, selling, or using these chemicals will face tough legal rules and penalties. The move aims to control these substances quickly while the DEA studies them further, affecting businesses and researchers handling these compounds.
2026-13580 — Schedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I
Starting July 6, 2026, the DEA plans to temporarily put 7-hydroxymitragynine above a certain amount into Schedule I, meaning it’s treated like the most tightly controlled drugs. This affects anyone who makes, sells, studies, or even just has this substance, bringing strict rules and penalties. The move aims to keep people safe while the government figures out the long-term plan.
Previous / Next Documents
Previous: 2026-04654 — Request for Nominations, Hydrographic Services Review Panel
NOAA is looking for new members to join the Hydrographic Services Review Panel, which helps make our oceans safer and smarter for boats and ships. If you’re interested, send your nomination by April 30, 2026. Five spots open starting January 2027, each lasting four years, so it’s a great chance to make waves in marine safety and technology!
Next: 2026-04656 — Japan Smaller Capitalization Fund, Inc. and Nomura Asset Management U.S.A. Inc.
Japan Smaller Capitalization Fund and Nomura Asset Management want to pay out long-term capital gains more often—up to 12 times a year instead of less frequently. This change affects investors in these funds by potentially giving them quicker access to earnings. The SEC is reviewing the request and will decide by March 31, 2026, unless someone asks for a hearing.